-
methods to well-annotated clinical cohorts to address questions in early detection, minimal residual disease, treatment response prediction, and resistance characterization. Our goal is to bridge technical
-
. Potential research directions include identifying biomarkers of sensitivity and resistance to anti-cancer compounds, defining mechanisms-of-action for cytotoxic small molecules, discovering genotype-specific
-
, chemical biology, AI, and pharmacogenomics to uncover how cancer cells respond to small-molecule therapies. Potential research directions include identifying biomarkers of sensitivity and resistance to anti
-
therapies. Discovering tumor-stromal, tumor-immune, and tumor-ECM programs that drive therapeutic resistance, cancer progression, and metastasis. Developing and applying computational/AI-enabled spatial omics